rGM-CSF increased the total number of myeloid DCs in mouse spleen, whereas the combination of rGM-CSF/rIL-4 increased the number of myeloid and lymphoid DCs in spleen and lymph nodes.

Mice were treated with rGM-CSF (GM) or the combination of rGM-CSF/rIL-4 (GM/IL-4), as described for Figure 1. Spleen cells (A) and pooled axillary and inguinal lymph nodes cells (B) cells were isolated, and FACS analysis was performed to determine the percentage of cells expressing the myeloid DC (CD11c⁺/CD11b⁺) or the lymphoid DC (CD11c⁺/CD118α⁺) phenotype. Percentages were multiplied by the number of total spleen or lymph node cells to determine the total spleen or lymph node cell number expressing each phenotype. Data represent the mean ± SE of 3 experiments. *P ≤ .05 compared with control.